Halma plc has acquired Dreampath Diagnostics, a Strasbourg-based provider of automated workflow solutions for anatomical pathology laboratories. The deal strengthens Halma’s healthcare capabilities in tissue sample traceability, archiving, and lifecycle management, supporting safer and more efficient diagnostics in a critical part of the patient journey.
Dreampath designs and supplies systems that help labs accurately track, store, and retrieve patient tissue samples throughout the diagnostic process. By replacing largely manual workflows, its technology improves traceability, reduces the risk of sample misidentification, enhances patient safety, and increases operational efficiency in a highly regulated environment.
The acquisition adds complementary capabilities to Halma’s Healthcare Sector, particularly within its Healthcare Enablement portfolio. Dreampath operates in a growing segment of the diagnostic pathway, supported by long-term drivers such as rising diagnostic volumes, increasing regulatory requirements around sample traceability, and stricter rules on long-term sample storage.
Dreampath will continue to operate as a standalone company within Halma’s Healthcare Sector, retaining its distinct culture and focus while benefiting from Halma’s support and global reach. The move reflects Halma’s broader strategy of investing in life‑saving technologies that improve safety and care quality across healthcare systems.
KEY QUOTES:
“Dreampath is a high-quality business in a growing area of diagnostics, driven by increasing demand for better healthcare, more testing alongside new treatments, and rising rates of chronic disease as populations age. It strengthens our Healthcare Sector by adding complementary capabilities and broadening our portfolio of technologies that support safer, more efficient and effective care. We are pleased to welcome Dreampath to Halma.”
Marc Ronchetti, Group Chief Executive, Halma plc
“We were looking for a long-term home that would value what makes Dreampath distinctive, support our people and culture, and help us accelerate our growth to continue protecting patients, sample by sample. Halma offers that combination of autonomy, ambition and support.”
Pablo Jordan, CEO, Dreampath Diagnostics
